Provider: View Press Release
Type: Link
Title: ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV | GSK
Description: According to UNAIDS, approximately 1.7 million children globally were living with HIV in 2020.
Provider: View Press Release
Type: Link
Title: ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period | GSK
Description: US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment.
Provider: View Press Release
Type: Link
Title: GSK to demonstrate its commitment to improving outcomes for patients with gynaecologic cancer at the 2022 SGO Annual Meeting | GSK
Description: The meeting will take place in Phoenix, Arizona, and virtually from 18-21 March 2022
Provider: View Press Release
Type: Link
Title: GSK announces appointments to Designate Haleon Board | GSK
Description: GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the appointment of six directors to the designate Board of Haleon.
Provider: View Press Release
Type: Link
Title: European Medicines Agency (EMA) accepts marketing authorisation application for daprodustat | GSK
Description: The EMA has validated the MAA for daprodustat, for the treatment of patients with anaemia of chronic kidney disease.
Provider: View Press Release
Type: Link
Title: GSK introduces Haleon to investors | GSK
Description: Global leader in consumer health set to be a newly independent company